FARALLON CAPITAL MANAGEMENT, L.L.C.FARALLON CAPITAL MANAGEMENT, L.L.C.

Institutional investor · Portfolio as of Q4 2023

Top Holdings158 positions

Checking export access…
Activity:
SPYSPY
PUT

State Street Spdr S&p 500 Etf Trust TR UNIT

12.3M$5.9B26.8%———
Increased
—

PIONEER NAT RES CO

3.1M$701.6M3.2%——
1 qtr
New
88

IQVIA Holdings Inc.

3M$685.1M3.1%$164.12+40.98%
21 qtrssince 2018-Q4
Increased
62

EXELIXIS INC

26.6M$639M2.9%$19.35+23.99%
21 qtrssince 2018-Q4
Increased
56

Thermo Fisher Scientific Inc

1.2M$638.6M2.9%$431.27+21.97%
17 qtrssince 2019-Q4
Increased
62

UnitedHealth Group Inc.

1.2M$633.1M2.9%$445.17+11.44%
4 qtrssince 2023-Q1
Decreased
0

TRANSUNION

9.1M$626.8M2.9%$86.03-20.94%
21 qtrssince 2018-Q4
Decreased
0

SALESFORCE COM INC

1.9M$506.7M2.3%$173.51+49.84%
17 qtrssince 2019-Q4
Decreased
0

Microsoft Corp.

1.3M$503.4M2.3%$213.45+72.49%
21 qtrssince 2018-Q4
Decreased
0

WABTEC

3.9M$499.8M2.3%$82.27+52.19%
21 qtrssince 2018-Q4
Increased
64

ARAMARK

16.9M$474.9M2.2%$25.48+7.26%
13 qtrssince 2020-Q4
Increased
71

NEW YORK TIMES CO

9.5M$464.3M2.1%$41.18+16.00%
15 qtrssince 2020-Q2
Increased
63

Alphabet Inc.

3.1M$442.3M2.0%$93.01+50.10%
21 qtrssince 2018-Q4
Decreased
0

HESS CORP

3M$428.9M2.0%——
1 qtr
New
71

CBRE GROUP INC

4.2M$395.3M1.8%$73.86+26.04%
2 qtrssince 2023-Q3
Decreased
0

S&P Global Inc

882,595$388.8M1.8%$298.42+36.62%
7 qtrssince 2022-Q2
Decreased
0

NASDAQ INC

6.6M$382M1.7%$56.48+0.26%
2 qtrssince 2023-Q3
Increased
79

Boston Scientific Corporation

5.8M$336.5M1.5%$41.25+40.16%
14 qtrssince 2020-Q3
Increased
56

INTUIT

533,000$333.1M1.5%$381.37+61.55%
5 qtrssince 2022-Q4
Decreased
0

CHARTER COMMUNICATIONS INC N

799,141$310.6M1.4%$439.82-76.49%
2 qtrssince 2023-Q3
Decreased
0
$21.9B
AUM
158
Positions
Q4 2023
Filing
HI score · 1.5/5
Quarterly 13F Value Change
-4%Q3'22$16.3B-5%Q4'22$15.5B+7%Q1'23$16.5B+1%Q2'23$16.7B+6%Q3'23$17.7B-10%Q4'23$16B
Activity profile
$ moved · Q4'23
New12%Increased37%Decreased11%Exited39%
Composition
Equity vs derivatives
Equity73%Puts27%Calls0%
Holding period
Avg 2.1 years
<1Q15%1-4Q19%1-2Y20%2Y+47%

FARALLON CAPITAL MANAGEMENT, L.L.C. manages $21.9B across 158 positions as of Q4 2023. Top holdings: SPY puts (26.8%), PXD (3.2%), IQV (3.1%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1.5/5.0.

Q4 2023 Summary

Active quarter - 29 new positions, 35 exits, 31 increased. Top move: PXD (NEW, conviction 88). Portfolio: $21.9B across 158 positions.

Top holdings by portfolio weight

Total AUM$16B
PXD3.21%
IQV3.13%
EXEL2.92%
TMO2.92%
UNH2.90%
TRU2.87%
CRM2.32%
MSFT2.30%
WAB2.29%
ARMK2.17%
Other2.12%

Portfolio allocation by GICS sector

Sectors11
Healthcare35.70%
Technology14.35%
Financial Services13.50%
Unknown12.68%
Industrials8.68%
Communication Services7.85%
Real Estate4.81%
Basic Materials1.74%
Consumer Cyclical0.31%
Utilities0.26%
Other0.12%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Technology, Financial Services
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Below Average(1.5 / 5.0)
Holdings P&L48
Conviction44
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
BBIOBBIOBRIDGEBIO PHARMA INC
Q4 2024 → Q2 2026+9M shares+$755.7M
7Q
CRNXCRNXCRINETICS PHARMACEUTICALS IN
Q4 2024 → Q2 2026+7.8M shares+$277M
5Q
BSXBSXBoston Scientific Corporation
Q2 2025 → Q2 2026+6.8M shares+$69.5M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used